表观遗传与肺癌耐药

Epigenetics and drug resistance in lung cancer

肺癌死亡率位居恶性肿瘤之首, 当前肺癌治疗中发生耐药是困阻临床工作者的重大难题。近年研究发现表观遗传学与肺癌耐药联系密切, 尤其在DNA甲基化、组蛋白修饰以及非编码RNA调节中发挥重要作用。通过以上三个特征探讨影响肺癌耐药的机制, 并针对机制探讨能有效改善肺癌耐药的药物, 可为临床工作中肺癌耐药相关问题提供解决思路, 对肺癌患者预后评估提供参考。

Lung cancer has the highest mortality rate among malignant tumors,and drug resistance in lung cancer treatment is currently a major challenge for clinical practitioners.Recent studies have found that epigenetics is closely linked to drug resistance in lung cancer,especially in DNA methylation,histone modifications and non-coding RNA regulation.By exploring the mechanisms affecting drug resistance in lung cancer through the above three features and exploring drugs that can effectively improve drug resistance in lung cancer in response to the mechanisms,it can provide ideas for solving the problems related to drug resistance in lung cancer in clinical work and provide a reference basis for prognostic assessment of lung cancer patients.